title: [Sjögren's syndrome and non-Hodgkin's lymphoma: from pathophysiology to treatment].
abstract: Although infrequent, the development of non-Hodgkin's lymphoma (NHL) during the course of Sjögren's syndrome represents a major complication. Nethertheless, most NHL developing in patients with Sjögren's syndrome are B cell lymphomas involving the marginal zone, localized to extranodal sites. Predictive factors include lymphadenopathy, splenomegaly, neutropenia, cryoglobulinemia and low C4 levels. The treatment of B cell lymphomas depends on its nature and localization. Biotherapies targeting the B lymphocyte, such as rituximab, a chimeric monoclonal anti-CD20 antibody, or more recently targeting BAFF can be proposed.
authors.affiliation: Assistance Publique-Hôpitaux de Paris, université Paris-Descartes, hôpital Cochin, pôle de médecine interne, Paris, France. veronique.le-guern@cch.aphp.fr
authors.forename: Véronique
authors.initials: V
authors.lastname: Le Guern
authors.forename: Luc
authors.initials: L
authors.lastname: Mouthon
mesh_terms: D002471:Cell Transformation, Neoplastic / Q000473:pathology; D018450:Disease Progression; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000175:diagnosis / Q000453:epidemiology / Q000209:etiology* / Q000628:therapy*; D015995:Prevalence; D011379:Prognosis; D012307:Risk Factors; D012859:Sjogren's Syndrome / Q000150:complications* / Q000175:diagnosis / Q000453:epidemiology / Q000628:therapy*